Transdermal scopolamine and urinary retention following urogynecologic surgery: a systematic review and meta-analysis

Introduction and hypothesis Both urogynecologic surgeries and transdermal scopolamine (TDS) patches are independently associated with postoperative urinary retention (POUR). It is unclear if the risk of POUR increases when these interventions are used in combination. This systematic review and meta-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International Urogynecology Journal 2023-08, Vol.34 (8), p.1689-1696
Hauptverfasser: Lanpher, Nick W., Schnittka, Emma M., Haggag, Akram
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1696
container_issue 8
container_start_page 1689
container_title International Urogynecology Journal
container_volume 34
creator Lanpher, Nick W.
Schnittka, Emma M.
Haggag, Akram
description Introduction and hypothesis Both urogynecologic surgeries and transdermal scopolamine (TDS) patches are independently associated with postoperative urinary retention (POUR). It is unclear if the risk of POUR increases when these interventions are used in combination. This systematic review and meta-analysis aim to synthesize current evidence to optimize clinical management and outcomes for patients undergoing urogynecologic procedures. Methods This systematic review was conducted in concordance with the PRISMA 2020 guidelines. MEDLINE, ClinicalTrials.gov, and Cochrane Library were searched. Publications were filtered by inclusion and exclusion criteria. Inclusion criteria required: (1) preoperative or perioperative application of TDS, (2) surgery indicated for stress urinary incontinence and/or pelvic organ prolapse, (3) results given for postoperative voiding trials, and (4) were available in English. Exclusion criteria included: (1) oral or parenteral formulations of scopolamine, (2) administration of alternative preoperative antiemetics, and (3) use of combination antiemetic therapy. Quality was assessed using the Joanna Briggs Institute Checklist. Publication bias was evaluated via the ROBINS-I assessment tool, and Egger regression and Begg and Mazumumdar rank correlation tests. A meta-analysis was conducted using Meta-Essentials Excel Workbook. Results Four publications were identified which complied with inclusion and exclusion criteria. Included studies comprised 752 patients (237 experimental group, 515 control group). All were retrospective cohort studies conducted via chart review in America. Meta-analysis revealed a risk ratio (RR) of 2.35 with a confidence interval (CI) of 0.61 to 9.07, indicating a positive association between TDS and POUR, but without statistical significance. Conclusions Current evidence suggests that TDS application may be associated with increased risk of POUR following urogynecologic procedures. While research on this topic is greatly limited, this systematic review and meta-analysis highlights that alternative antiemetic therapy may be necessary for patients undergoing such interventions in effort to limit the risk of POUR.
doi_str_mv 10.1007/s00192-023-05467-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2771332513</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2848584094</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-7aff39805fac51cd9c695ee644f7245b76847244959d913b2d1c3e7d032a3d723</originalsourceid><addsrcrecordid>eNp9kU2PFCEQhonRuOPoH_BgOvHiBQUKmsab2fiVbOJlPROGrp6woWGEbjf97xd3Vk08eCkqVU-9Reol5CVnbzlj-l1ljBtBmQDKlOw1HR6RHZcAFFrtMdkxA5qC7MUFeVbrDWNMMsWekgvoNTdSmh1Zr4tLdcQyu9hVn085ujkk7Fwau7WE5MrWFVwwLSGnbsox5tuQjq2Xj1tCn2M-Bt_VtRyxbO8719WtLji7pVUL_gx4e6814-KoSy5uNdTn5MnkYsUXD--efP_08fryC7369vnr5Ycr6kH0C9VumsAMTE3OK-5H43ujEHspJy2kOuh-kC2RRpnRcDiIkXtAPTIQDkYtYE_enHVPJf9YsS52DtVjjC5hXqsVWnMAoVrYk9f_oDd5Le2_jRrkoAbJjGyUOFO-5FoLTvZUwtxuZDmzv0yxZ1NsM8Dem2KHNvTqQXo9zDj-GfntQgPgDNTWSu2Of3f_R_YODeWZNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2848584094</pqid></control><display><type>article</type><title>Transdermal scopolamine and urinary retention following urogynecologic surgery: a systematic review and meta-analysis</title><source>SpringerLink Journals</source><creator>Lanpher, Nick W. ; Schnittka, Emma M. ; Haggag, Akram</creator><creatorcontrib>Lanpher, Nick W. ; Schnittka, Emma M. ; Haggag, Akram</creatorcontrib><description>Introduction and hypothesis Both urogynecologic surgeries and transdermal scopolamine (TDS) patches are independently associated with postoperative urinary retention (POUR). It is unclear if the risk of POUR increases when these interventions are used in combination. This systematic review and meta-analysis aim to synthesize current evidence to optimize clinical management and outcomes for patients undergoing urogynecologic procedures. Methods This systematic review was conducted in concordance with the PRISMA 2020 guidelines. MEDLINE, ClinicalTrials.gov, and Cochrane Library were searched. Publications were filtered by inclusion and exclusion criteria. Inclusion criteria required: (1) preoperative or perioperative application of TDS, (2) surgery indicated for stress urinary incontinence and/or pelvic organ prolapse, (3) results given for postoperative voiding trials, and (4) were available in English. Exclusion criteria included: (1) oral or parenteral formulations of scopolamine, (2) administration of alternative preoperative antiemetics, and (3) use of combination antiemetic therapy. Quality was assessed using the Joanna Briggs Institute Checklist. Publication bias was evaluated via the ROBINS-I assessment tool, and Egger regression and Begg and Mazumumdar rank correlation tests. A meta-analysis was conducted using Meta-Essentials Excel Workbook. Results Four publications were identified which complied with inclusion and exclusion criteria. Included studies comprised 752 patients (237 experimental group, 515 control group). All were retrospective cohort studies conducted via chart review in America. Meta-analysis revealed a risk ratio (RR) of 2.35 with a confidence interval (CI) of 0.61 to 9.07, indicating a positive association between TDS and POUR, but without statistical significance. Conclusions Current evidence suggests that TDS application may be associated with increased risk of POUR following urogynecologic procedures. While research on this topic is greatly limited, this systematic review and meta-analysis highlights that alternative antiemetic therapy may be necessary for patients undergoing such interventions in effort to limit the risk of POUR.</description><identifier>ISSN: 0937-3462</identifier><identifier>EISSN: 1433-3023</identifier><identifier>DOI: 10.1007/s00192-023-05467-8</identifier><identifier>PMID: 36719449</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antiemetics ; Gynecology ; Medicine ; Medicine &amp; Public Health ; Meta-analysis ; Original Article ; Systematic review ; Urinary retention ; Urology</subject><ispartof>International Urogynecology Journal, 2023-08, Vol.34 (8), p.1689-1696</ispartof><rights>The International Urogynecological Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The International Urogynecological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-7aff39805fac51cd9c695ee644f7245b76847244959d913b2d1c3e7d032a3d723</cites><orcidid>0000-0001-9231-3028</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00192-023-05467-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00192-023-05467-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36719449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanpher, Nick W.</creatorcontrib><creatorcontrib>Schnittka, Emma M.</creatorcontrib><creatorcontrib>Haggag, Akram</creatorcontrib><title>Transdermal scopolamine and urinary retention following urogynecologic surgery: a systematic review and meta-analysis</title><title>International Urogynecology Journal</title><addtitle>Int Urogynecol J</addtitle><addtitle>Int Urogynecol J</addtitle><description>Introduction and hypothesis Both urogynecologic surgeries and transdermal scopolamine (TDS) patches are independently associated with postoperative urinary retention (POUR). It is unclear if the risk of POUR increases when these interventions are used in combination. This systematic review and meta-analysis aim to synthesize current evidence to optimize clinical management and outcomes for patients undergoing urogynecologic procedures. Methods This systematic review was conducted in concordance with the PRISMA 2020 guidelines. MEDLINE, ClinicalTrials.gov, and Cochrane Library were searched. Publications were filtered by inclusion and exclusion criteria. Inclusion criteria required: (1) preoperative or perioperative application of TDS, (2) surgery indicated for stress urinary incontinence and/or pelvic organ prolapse, (3) results given for postoperative voiding trials, and (4) were available in English. Exclusion criteria included: (1) oral or parenteral formulations of scopolamine, (2) administration of alternative preoperative antiemetics, and (3) use of combination antiemetic therapy. Quality was assessed using the Joanna Briggs Institute Checklist. Publication bias was evaluated via the ROBINS-I assessment tool, and Egger regression and Begg and Mazumumdar rank correlation tests. A meta-analysis was conducted using Meta-Essentials Excel Workbook. Results Four publications were identified which complied with inclusion and exclusion criteria. Included studies comprised 752 patients (237 experimental group, 515 control group). All were retrospective cohort studies conducted via chart review in America. Meta-analysis revealed a risk ratio (RR) of 2.35 with a confidence interval (CI) of 0.61 to 9.07, indicating a positive association between TDS and POUR, but without statistical significance. Conclusions Current evidence suggests that TDS application may be associated with increased risk of POUR following urogynecologic procedures. While research on this topic is greatly limited, this systematic review and meta-analysis highlights that alternative antiemetic therapy may be necessary for patients undergoing such interventions in effort to limit the risk of POUR.</description><subject>Antiemetics</subject><subject>Gynecology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Meta-analysis</subject><subject>Original Article</subject><subject>Systematic review</subject><subject>Urinary retention</subject><subject>Urology</subject><issn>0937-3462</issn><issn>1433-3023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU2PFCEQhonRuOPoH_BgOvHiBQUKmsab2fiVbOJlPROGrp6woWGEbjf97xd3Vk08eCkqVU-9Reol5CVnbzlj-l1ljBtBmQDKlOw1HR6RHZcAFFrtMdkxA5qC7MUFeVbrDWNMMsWekgvoNTdSmh1Zr4tLdcQyu9hVn085ujkk7Fwau7WE5MrWFVwwLSGnbsox5tuQjq2Xj1tCn2M-Bt_VtRyxbO8719WtLji7pVUL_gx4e6814-KoSy5uNdTn5MnkYsUXD--efP_08fryC7369vnr5Ycr6kH0C9VumsAMTE3OK-5H43ujEHspJy2kOuh-kC2RRpnRcDiIkXtAPTIQDkYtYE_enHVPJf9YsS52DtVjjC5hXqsVWnMAoVrYk9f_oDd5Le2_jRrkoAbJjGyUOFO-5FoLTvZUwtxuZDmzv0yxZ1NsM8Dem2KHNvTqQXo9zDj-GfntQgPgDNTWSu2Of3f_R_YODeWZNg</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Lanpher, Nick W.</creator><creator>Schnittka, Emma M.</creator><creator>Haggag, Akram</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9231-3028</orcidid></search><sort><creationdate>20230801</creationdate><title>Transdermal scopolamine and urinary retention following urogynecologic surgery: a systematic review and meta-analysis</title><author>Lanpher, Nick W. ; Schnittka, Emma M. ; Haggag, Akram</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-7aff39805fac51cd9c695ee644f7245b76847244959d913b2d1c3e7d032a3d723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antiemetics</topic><topic>Gynecology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Meta-analysis</topic><topic>Original Article</topic><topic>Systematic review</topic><topic>Urinary retention</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanpher, Nick W.</creatorcontrib><creatorcontrib>Schnittka, Emma M.</creatorcontrib><creatorcontrib>Haggag, Akram</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International Urogynecology Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanpher, Nick W.</au><au>Schnittka, Emma M.</au><au>Haggag, Akram</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transdermal scopolamine and urinary retention following urogynecologic surgery: a systematic review and meta-analysis</atitle><jtitle>International Urogynecology Journal</jtitle><stitle>Int Urogynecol J</stitle><addtitle>Int Urogynecol J</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>34</volume><issue>8</issue><spage>1689</spage><epage>1696</epage><pages>1689-1696</pages><issn>0937-3462</issn><eissn>1433-3023</eissn><abstract>Introduction and hypothesis Both urogynecologic surgeries and transdermal scopolamine (TDS) patches are independently associated with postoperative urinary retention (POUR). It is unclear if the risk of POUR increases when these interventions are used in combination. This systematic review and meta-analysis aim to synthesize current evidence to optimize clinical management and outcomes for patients undergoing urogynecologic procedures. Methods This systematic review was conducted in concordance with the PRISMA 2020 guidelines. MEDLINE, ClinicalTrials.gov, and Cochrane Library were searched. Publications were filtered by inclusion and exclusion criteria. Inclusion criteria required: (1) preoperative or perioperative application of TDS, (2) surgery indicated for stress urinary incontinence and/or pelvic organ prolapse, (3) results given for postoperative voiding trials, and (4) were available in English. Exclusion criteria included: (1) oral or parenteral formulations of scopolamine, (2) administration of alternative preoperative antiemetics, and (3) use of combination antiemetic therapy. Quality was assessed using the Joanna Briggs Institute Checklist. Publication bias was evaluated via the ROBINS-I assessment tool, and Egger regression and Begg and Mazumumdar rank correlation tests. A meta-analysis was conducted using Meta-Essentials Excel Workbook. Results Four publications were identified which complied with inclusion and exclusion criteria. Included studies comprised 752 patients (237 experimental group, 515 control group). All were retrospective cohort studies conducted via chart review in America. Meta-analysis revealed a risk ratio (RR) of 2.35 with a confidence interval (CI) of 0.61 to 9.07, indicating a positive association between TDS and POUR, but without statistical significance. Conclusions Current evidence suggests that TDS application may be associated with increased risk of POUR following urogynecologic procedures. While research on this topic is greatly limited, this systematic review and meta-analysis highlights that alternative antiemetic therapy may be necessary for patients undergoing such interventions in effort to limit the risk of POUR.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36719449</pmid><doi>10.1007/s00192-023-05467-8</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9231-3028</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0937-3462
ispartof International Urogynecology Journal, 2023-08, Vol.34 (8), p.1689-1696
issn 0937-3462
1433-3023
language eng
recordid cdi_proquest_miscellaneous_2771332513
source SpringerLink Journals
subjects Antiemetics
Gynecology
Medicine
Medicine & Public Health
Meta-analysis
Original Article
Systematic review
Urinary retention
Urology
title Transdermal scopolamine and urinary retention following urogynecologic surgery: a systematic review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T08%3A53%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transdermal%20scopolamine%20and%20urinary%20retention%20following%20urogynecologic%20surgery:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=International%20Urogynecology%20Journal&rft.au=Lanpher,%20Nick%20W.&rft.date=2023-08-01&rft.volume=34&rft.issue=8&rft.spage=1689&rft.epage=1696&rft.pages=1689-1696&rft.issn=0937-3462&rft.eissn=1433-3023&rft_id=info:doi/10.1007/s00192-023-05467-8&rft_dat=%3Cproquest_cross%3E2848584094%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2848584094&rft_id=info:pmid/36719449&rfr_iscdi=true